Amgen Q2 revenue tops $10B; IMDELLTRA + durvalumab advances
Amgen reported Q2 2026 revenue topping $10B, driven by six key drug groups. The update also cites Phase III progress for IMDELLTRA + durvalumab in ES—SCLC, a shorter infusion monitoring approach, an Opdivo biosimilar filing, and continued development including MariTide and a broad obesity Phase III program.